The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel
Download in electronic PDF format for $75
Abstract: The purpose of this study was to evaluate the in vitro release and ex vivo penetration of baclofen following incorporation into a 2% poloxamer lecithin organogel. Franz cells were utilized for both the release and penetration studies. Semi-permeable dialysis membranes were used for the release testing, and porcine skin was used as the model skin for the penetration study. Baclofen release and penetration at predetermined time points were assessed using high-performance liquid chromatographic analysis. Results demonstrated that baclofen release from the poloxamer lecithin organogel was significantly higher than its penetration through porcine skin. The amount of baclofen released by the poloxamer lecithin organogel was linear up to 12 hours. Approximately 20% of applied drug was released over the duration of the study period. In comparison with drug released, the ex vivo penetration of baclofen through porcine skin was very low with only minute detectable quantities (significantly less than 1%) after the 12-ho
Related Keywords:
baclofen, transdermal delivery, topical preparations, skin penetration, poloxamer lecithin organogel, dermal application, formulation, PLO, muscle relaxant
Related Categories:
EXCIPIENTS, FORMULATIONS, PEER-REVIEWED, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel
Arnold John J, Asbill Scott
|
Nov/Dec 2009
Pg. 569-571
|
Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel
Woodall Rachel, Arnold John J, McKay Doug, Abill C Scott
|
May/Jun 2013
Pg. 247-253
|
Veterinary Transdermal Medications: A to Z
Davidson Gigi S
|
Mar/Apr 2003
Pg. 106-113
|
Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery
Boddu Sai HS, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
|
May/Jun 2014
Pg. 256-261
|
The Use of Pluronic Lecithin Organogels in the Transdermal Delivery of Drugs
Bramwell Bethany L, Williams LaVonn A
|
Jan/Feb 2012
Pg. 62-63
|
In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations
Heustess Allie, Asbill Scott, Eagerton David, Arnold John
|
Nov/Dec 2014
Pg. 512-515
|
Skin Penetration and Antinociception of Topical Gabapentin Formulations
Bryson Evan, Asbill Scott, Sweitzer Sarah
|
Nov/Dec 2014
Pg. 504-511
|
Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin
Le Uyen Minh, Baltzley Sarah, AlGhananeem Abeer
|
Nov/Dec 2018
Pg. 498-503
|
Effect of Penetration Enhancers on the Percutaneous Delivery of Pain Management Actives
Trimble John, Light Bob
|
May/Jun 2016
Pg. 250-256
|
The History of Pluronic Lecithin Organogel: An Interview With Marty Jones, BSPharm, FACA, FIACP
Allen Loyd V Jr
|
May/Jun 2003
Pg. 180-183
|
Baclofen 5%, Capcaicin 0.075%, Ketoprofen 10%, and Tetracaine 2% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Nov/Dec 2010
Pg. 513
|
Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
|
Jan/Feb 2022
Pg. 65-71
|
Baclofen 5%, Gabapentin 5%, Ketoprofen 10%, and Lidocaine 5% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Nov/Dec 2010
Pg. 514
|
Amitriptyline Hydrochloride 2%, Baclofen 5%, Ketamine Hydrochloride 5%, Ketoprofen 10% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Nov/Dec 2010
Pg. 512
|
Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
|
Mar/Apr 2004
Pg. 101-105
|
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study
Glisson James K, Wood Rebecca L, Kyle Patrick B, Cleary John D
|
May/Jun 2005
Pg. 242-246
|
Stability of Methimazole in Poloxamer Lecithin Organogel to Determine Beyond-Use Date
Pignato Alyssa, Pankaskie Marvin, Birnie Christine
|
Nov/Dec 2010
Pg. 522-525
|
Effect of Penetration Enhancers on the Percuaneous Delivery of Hormone Replacement Actives
Trimble John O, Light Bob
|
Nov/Dec 2017
Pg. 530-535
|
BHR in PLO Gel (Benadryl, Haldol, and Reglan in Pluronic Lecithin Organogel)
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 322
|
Skin Permeation and Antinociception of Compounded Topical Cyclobenzaprine Hydrochloride Formulations
Bryson Evan, Hartman Rachel, Arnold John, Gorman Greg, Sweitzer Sarah.Asbill Scott
|
Mar/Apr 2015
Pg. 161-166
|
Return to Top |